Search research articles
Contact Us
Filters
Showing results (31-40 of 235) with videos related to
Page
of 24
Sort By:
Arteriosclerosis, Thrombosis, and Vascular Biology
|
July 9, 2004
Vitamin E is not deficient in human atherosclerotic plaques
Anatol Kontush, M John Chapman, Roland Stocker
Journal of Lipid Research
|
April 2, 2013
Unraveling the complexities of the HDL lipidome
Anatol Kontush, Marie Lhomme, M John Chapman
Clinical Chemistry
|
September 2, 2020
LDL Cholesterol: 'The Times They Are A-Changin'
M John Chapman, Philippe Giral, Patrice Therond
Circulation
|
October 22, 2014
Letter by Giral et al regarding article, "lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin)"
Philippe Giral, Dominique Simon, M John Chapman
Pharmacogenomics
|
February 22, 2011
Impact of genetic variation in the SLCO1B1 gene on statin efficacy in low-density lipoprotein cholesterol-lowering therapy
Philippe Couvert, M John Chapman, Alain Carrié
Nature Clinical Practice. Cardiovascular Medicine
|
April 24, 2008
Spotlight on HDL-raising therapies: insights from the torcetrapib trials
Anatol Kontush, Maryse Guérin, M John Chapman
Arteriosclerosis, Thrombosis, and Vascular Biology
|
August 16, 2003
Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress
Anatol Kontush, Sandrine Chantepie, M John Chapman
Journal of Clinical Lipidology
|
August 21, 2019
PCSK9 inhibition, atherosclerotic cardiovascular disease, and health economics: Challenges at the crossroads
Lieven Annemans, Jane K Stock, M John Chapman
European Heart Journal
|
March 14, 2013
The conundrum of C-reactive protein as a risk marker for cardiovascular risk assessment: insight from EPIC-Norfolk and JUPITER
M John Chapman, Philippe Giral, Philip J Barter
Journal of the American College of Cardiology
|
January 29, 2025
Plasma Triglyceride Reduction and Cardiovascular Risk in ODYSSEY Outcomes Trial: Interpret With Caution
Chris J Packard, Jan Borén, M John Chapman
Page
of 24
Search research articles
Search
Showing results (31-40 of 235) with videos related to
Sort By:
Page
of 24
Arteriosclerosis, Thrombosis, and Vascular Biology
|
July 9, 2004
Vitamin E is not deficient in human atherosclerotic plaques
Anatol Kontush, M John Chapman, Roland Stocker
Journal of Lipid Research
|
April 2, 2013
Unraveling the complexities of the HDL lipidome
Anatol Kontush, Marie Lhomme, M John Chapman
Clinical Chemistry
|
September 2, 2020
LDL Cholesterol: 'The Times They Are A-Changin'
M John Chapman, Philippe Giral, Patrice Therond
Circulation
|
October 22, 2014
Letter by Giral et al regarding article, "lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin)"
Philippe Giral, Dominique Simon, M John Chapman
Pharmacogenomics
|
February 22, 2011
Impact of genetic variation in the SLCO1B1 gene on statin efficacy in low-density lipoprotein cholesterol-lowering therapy
Philippe Couvert, M John Chapman, Alain Carrié
Nature Clinical Practice. Cardiovascular Medicine
|
April 24, 2008
Spotlight on HDL-raising therapies: insights from the torcetrapib trials
Anatol Kontush, Maryse Guérin, M John Chapman
Arteriosclerosis, Thrombosis, and Vascular Biology
|
August 16, 2003
Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress
Anatol Kontush, Sandrine Chantepie, M John Chapman
Journal of Clinical Lipidology
|
August 21, 2019
PCSK9 inhibition, atherosclerotic cardiovascular disease, and health economics: Challenges at the crossroads
Lieven Annemans, Jane K Stock, M John Chapman
European Heart Journal
|
March 14, 2013
The conundrum of C-reactive protein as a risk marker for cardiovascular risk assessment: insight from EPIC-Norfolk and JUPITER
M John Chapman, Philippe Giral, Philip J Barter
Journal of the American College of Cardiology
|
January 29, 2025
Plasma Triglyceride Reduction and Cardiovascular Risk in ODYSSEY Outcomes Trial: Interpret With Caution
Chris J Packard, Jan Borén, M John Chapman
Page
of 24